Crispr stock reversed lower Monday, while Intellia stock surged, on promising updates for their gene-editing efforts.

Promising results from a small clinical trial highlight a growing interest in designing gene-editing treatments for common ...

An experimental gene-editing treatment shows promise for permanently lowering levels of cholesterol and triglycerides, ...

CRISPR ended 2023 with a bang. In November, the gene editing tool scored its first clinical approval for treating sickle cell anemia and beta-thalassemia in the United Kingdom. These painful blood ...

Dr. Mark Pennesi looks on as staff at school's Casey Eye Institute perform the first-ever in vivo CRISPR gene edit procedure for the BRILLIANCE clinical trial in Portland. Kristyna Wentz-Graff/OHSU ...

Labroots invites you to the 4th Annual Event in the CRISPR Virtual Event Series! This event will continue the conversation of the abilities of CRISPR-based editing, next-gen editing tools, precision ...

Last month saw the first-ever approval of a gene therapy that uses the CRISPR–Cas9 gene-editing tool, a treatment for the blood conditions sickle-cell disease and β-thalassaemia that works by ...

GenEditBio Limited ("GenEditBio"), a Hong Kong -headquartered clinical-stage biotechnology company specializing in novel deliveries, including lipid nanoparticle (LNP)-based delivery systems, ...

Intellia Therapeutics doesn’t need to re-dose patients with a CRISPR gene edited therapy for transthyretin (ATTR) amyloidosis. But new data suggests it could be done. Gene therapies and gene editing ...

CRISPR Therapeutics and Vertex plan to file for regulatory approval by the end of 2022. The rest of CRISPR Therapeutics’ pipeline is either in early (Phase 1) or pre-clinical stages of development.